Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Bernstein analysts maintained their positive stance on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $1,100.00. The endorsement comes amidst a competitive ...

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...

Pharma stocks have underperformed the market in the fourth quarter with the Stoxx Europe 600 Health Care index--which is heavily dominated by Europe's six largest pharma companies--down 9.4% against a ...

Alphabet also remains a popular pick among hedge fund managers. According to Insider Monkey data, 202 hedge fund investors ...

Tori Allen says she's thrilled to have lost 80 pounds since she went on Wegovy, one of the GLP-1 drugs that more and more people are using to treat diabetes or lose weight.